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Abstract
Debridement is the process of removal of necrotic and infected tissue to clean a
wound or burn and expedite healing. Proteases such as papain, bromelain, and colla-
genase that promote debridement by degrading proteins in the dead tissue are in use
today. However, the only method to measure debriding efficacy in vitro is the fluo-
rescent monitoring of the digestion of an Artificial Wound Eschar (AWE) substrate.
This AWE substrate contains a pellet of only three eschar matrix proteins collagen,
elastin, and fibrin which do not account for the complexity and the composition of
necrotic tissue. Here, we describe an ex vivo method using dry necrotic full thickness
human skin and ortho-phthalaldehyde (OPA), a molecule commonly used for sensitive
fluorimetric protein detection to monitor debridement activity. We advocate this
simple yet sensitive approach to detect debridement efficacy that can readily be used
commercially to benchmark products prior to in vivo testing.
1 | INTRODUCTION
Proteases catalyze the breakdown of polypeptides or proteins by spe-
cific cleavage of peptide bonds in their substrates via hydrolysis to pre-
serve tissue integrity.1,2 Identified proteases are classified into seven
groups based on the nature of their catalytic site and optimal pH at
which they are active. These include aspartic proteases, cysteine prote-
ases, serine proteases, metalloproteases, threonine proteases, glutamic
acid proteases, and asparagine peptidases.3 Proteases promote wound
healing by degrading dead tissue4 and they have been used as active
molecules in dermatological products to treat necrotic wounds or non-
healing wounds such as skin ulcers. Proteases promote debridement,
defined as the removal of non-viable or necrotic tissue, foreign bodies,
and bacteria from acute or chronic wounds to expose the underlying
viable tissue.5,6 Various types of wound debridement techniques are
currently available in clinical practice: autolytic, surgical, mechanical,
bio-debridement, and enzymatic/chemical debridement.7,8 Enzymatic
debridement agents such as papain, bromelain, ficin, collagenase, and
trypsin have been developed as they work together with the endoge-
nous enzymes in the wound to clear the dead tissue.8-10
However, currently, enzymatic digestion of proteins is monitored
either in-gel or in a solution using mostly serine or cysteine proteases
and further analysis to determine the protein concentration. There-
fore, it is desirable to objectively monitor the efficacy of enzymatic
debridement in whole tissue such as burned or necrotic skin in vitro.
Currently, the standard model to quantify debriding efficacy in vitro
for assessing protease activity/protein digestion is the artificial wound
Eschar (AWE) substrate developed by Shi et al.11 This AWE comprises
of a pellet of three wound related extracellular matrix proteins, typi-
cally collagen, elastin, and fibrin, each of them tagged with a different
fluorophore. The gradual degradation of this matrix can be measured
by progressive increase in fluorescence intensity in the bottom cham-
ber of a Franz diffusion cell.11 However, this model utilizes only
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artificial proteins and cannot account for the complexity and composi-
tion of necrotic tissue (ie, other proteins, lipids, saccharides, blood
vessels, coagulation products, bacteria). Therefore, it would be desir-
able for the scientific community and debriding product industry to
have a method available to accurately measure proteolytic digestion
in a realistic skin sample that contains all the aforementioned
constituents.
We propose a new method based on ortho-phthalaldehyde
(OPA), a molecule commonly used in sensitive fluorimetric protein
detection such as residual protein on surgical devices, biofilm quantifi-
cation, and gas chromatographic peptide labeling12 and also for total
protein quantification in solution form.13 OPA is not fluorescent in its
native form, but once activated by reduced sulfhydryl groups it specifi-
cally reacts with primary amines in proteins to produce a fluorescent
indole derivative, thus resulting in high sensitivity with low background
(ng-level limits of detection for amino acids) (Figure 1A).13 Primary
amino groups are only found at the N-terminus of proteins and at the
“ε” position of lysines. As a primary amino group is produced after every
proteolytic cleavage event, the concentration of primary amino groups
is an adequate proxy for the extent of sample digestion, more so than
the total protein concentration, which would also include dissolved,
undigested macromolecules and does not increase with proteolysis. In
the present communication, we describe the application of OPA in the
assessment of the debriding efficacy of proteolytic enzymes.
In our study, a dry necrotic full thickness human skin is placed in
contact with the debriding proteolytic solution and the digested pep-
tides are separated by centrifugation at 24 hours. The advantage of
this technique over the previous analytical protocol11 is the fact that
it uses natural skin and it measures overall protein digestion instead
of only three proteins (fibrin, collagen, and elastin) as in the AWE.
F IGURE 1 A, Reaction of OPA
and primary amino groups in the
presence of sulfhydryl groups yields
a fluorophore which can be detected
Fluorimetrically. B,C, Linearity
response of the assay over
1-10 mg/mL (B) and, over
20-100 mg/mL protein
concentration (C)
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Moreover, it does not require a complex Franz cell chamber and the
results are not skewed by the product diffusion rate through a filter
membrane as in the Franz cell chamber.
2 | MATERIALS AND METHODS
2.1 | Materials
Healthy skin samples from abdominal reduction surgery were obtained
from the Royal London Hospital. The skin was cut into small pieces about
100 mg in weight and incubated at 37C in a hot air room for 3 days to
generate dry full thickness necrotic skin (Figure 2A,B). OPA, papain, stem
bromelain, ficin, and β-mercaptoethanol were obtained from Sigma. The
plate reader used was a Synergy HT microplate reader (cat. 12 926 527,
Bio-Tek Instruments, Thermo Fisher Scientific, UK).
2.2 | Methods
Linearity of the test response to protein concentration was carried
out using BSA: 20 μL BSA solutions (1-10 or 10-100 mg/mL in PBS)
were dispensed in a 96-well plate, added with 200 μL of an OPA solu-
tion (1 mg/mL PBS, supplemented with 0.2% β-mercaptoethanol),
and, following 5 minute incubation, fluorescence was read (excitation
at 360 nm, emission at 480 nm). The 5-minute time period was cho-
sen as the point when the reaction was kinetically complete as mea-
sured in a separate kinetic run (data not shown).
2.3 | Debridement assay
The skin samples were rinsed with PBS until the OPA reading was
insignificantly different than that of PBS to remove any material on
the surface of the skin that may increase the background readings.
For each test, four solutions were prepared as follows:
PBS: PBS alone (Negative control).
P: Papain 2 mg/mL in PBS (No substrate control).
S: Dry full thickness necrotic skin in PBS (No enzyme control).
PS: Papain 2 mg/mL in PBS plus dry full thickness necrotic skin
(Positive).
For experiments involving skin (S and PS), the volume of the PBS
or debriding solution was 20 times the weight of the eschar; this
allowed us to take into account slight differences in the weight of the
skin. The vials were incubated at 37C for 24 hours. At the end of this
period, 20 μL of each sample were transferred in triplicate onto a
96 well plate and added with 200 μL of the OPA solution. Fluores-
cence was read after 5 minutes incubation. The subsequent debride-
ment assay involving the other proteases followed the same setup
with each enzyme substituted for papain.
3 | RESULTS
Results of the linearity experiments (Figure 1B,C) confirmed the line-
arity of the assay over the 1 to 10 mg/mL range. Above 20 mg/mL
(1000 fluorescence units) the response was no longer linear indicating
the need to dilute samples exceeding this reading.
The results of the debridement assay (Figure 2C) show a signifi-
cant increase in fluorescence in the enzyme plus dry full thickness
necrotic skin sample, this being greater than the sum of that of skin
and enzyme alone, indicating the generation of additional free amino
groups, a consequence of skin digestion. We then compared the
F IGURE 2 A,B, human skin before (A) and (B) after 72 hours in a
warm room to generate dried full thickness necrotic skin. C, Fluorescence
monitoring by OPA assay of the proteolysis of eschar by papain showing
a greater increase vs eschar and papain alone. PBS, phosphate buffered
saline; P, papain; S, eschar without papain; PS, Eschar with papain. D,
comparison of the debriding efficacy at 24 hours of three proteolytic
enzymes using the OPA assay: (papain (PS), bromelain (BS) and ficin (FS))
on eschar showing significantly greater digestion vs control eschar in PBS
(S). Results are represented as the mean ± SD for n = 3 experiments, each
measured three times. Statistical analysis was carried out using the
Student t-test (***P < .001)
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debriding efficacy of three proteolytic enzymes: papain, bromelain,
and ficin using the same experimental conditions. Figure 2D shows
significantly greater debridement compared to control, with bromelain
approximately twice as potent at debriding as papain and ficin.
4 | DISCUSSION
Wound debridement is a medical procedure aimed at facilitating the
healing of chronic wounds and preventing their infection. Although it
is normally carried out surgically, there is a demand for non-surgical
alternatives such as enzymatic debridement because surgical debride-
ment requires specialized medical personnel and is associated with
risks of bleeding and damage to the surrounding healthy tissues and
vital structures such as nerves.14 Enzymatic debridement is also used
in combination with other techniques such as surgical debridement
for better treatment of chronic wounds.15
Some products, based on papain, bromelain, and collagenase, have
been developed and marketed for this purpose. In this respect, it would
be desirable for the research community to have available a tool to
benchmark the efficacy of debriding formulations so as to optimize
their composition before progressing toward expensive in vivo trials.
To our knowledge, the only one such assay is the AWE protocol devel-
oped by Smith and Nephew11 which, however, relies on an artificial
eschar model not representative of actual tissue complexity and relying
on an apparatus (the Franz diffusion cell) which further complicates
readouts and introduces perturbations such as diffusion. In this work,
we propose a completely novel method directly applicable to human
tissue samples, which is easy to set up, fast, and inexpensive. The aim
of the experiments presented in this report was to validate a new assay
for enzymatic debridement that was closer to human tissue than the
artificial eschar and we did not investigate much shorter clinically rele-
vant time points, such as those prescribed for commercial enzymatic
debriding formulations. Moreover, by exploiting the fluorescent deriva-
tization of primary amino groups, only generated during proteolytic
hydrolysis of the peptide bond, it achieves a higher level of sensitivity
and specificity than total protein assays and can be used by researchers
to characterize debriding formulations in a more realistic setting includ-
ing against wet necrotic eschar involving biofilm and burn tissue.
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